

Roger Reddel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5412029/publications.pdf>

Version: 2024-02-01

196
papers

19,854
citations

8181

76
h-index

11939

134
g-index

206
all docs

206
docs citations

206
times ranked

17404
citing authors

#	ARTICLE	IF	CITATIONS
1	qmotif: determination of telomere content from whole-genome sequence data. <i>Bioinformatics Advances</i> , 2022, 2, .	2.4	5
2	Pan-cancer proteomic map of 949 human cell lines. <i>Cancer Cell</i> , 2022, 40, 835-849.e8.	16.8	52
3	Targeted Therapy of <i>TERT</i> -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1438-1451.	7.0	20
4	Alternative lengthening of telomeres is not synonymous with mutations in <i>ATRX/DAXX</i> . <i>Nature Communications</i> , 2021, 12, 1552.	12.8	24
5	Functional characterization of miR-708 microRNA in telomerase positive and negative human cancer cells. <i>Scientific Reports</i> , 2021, 11, 17052.	3.3	4
6	A novel cause of <i>DKC1</i> related bone marrow failure: Partial deletion of the 3' untranslated region. <i>EJHaem</i> , 2021, 2, 157-166.	1.0	1
7	The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity. <i>Cancers</i> , 2021, 13, 5369.	3.7	10
8	Role of <i>POT1</i> in Human Cancer. <i>Cancers</i> , 2020, 12, 2739.	3.7	36
9	Fibroblast-Derived <i>STC-1</i> Modulates Tumor-Associated Macrophages and Lung Adenocarcinoma Development. <i>Cell Reports</i> , 2020, 31, 107802.	6.4	18
10	Strategies to enable large-scale proteomics for reproducible research. <i>Nature Communications</i> , 2020, 11, 3793.	12.8	75
11	Intronic <i>TP53</i> Polymorphisms Are Associated with Increased \uparrow <i>TP53</i> Transcript, Immune Infiltration and Cancer Risk. <i>Cancers</i> , 2020, 12, 2472.	3.7	13
12	End Products of Telomere Research. <i>Cell Stem Cell</i> , 2020, 26, 804-805.	11.1	0
13	Addressing the Challenges of High-Throughput Cancer Tissue Proteomics for Clinical Application: <i>ProCan</i> . <i>Proteomics</i> , 2019, 19, e1900109.	2.2	25
14	The <i>FANCM-BLM-TOP3A-RMI</i> complex suppresses alternative lengthening of telomeres (ALT). <i>Nature Communications</i> , 2019, 10, 2252.	12.8	125
15	Synthetic lethality of cytolytic HSV-1 in cancer cells with <i>ATRX</i> and <i>PML</i> deficiency. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	19
16	\uparrow <i>TP53</i> isoform promotes tumour invasion and metastasis via interleukin-6 activation of <i>JAK-STAT</i> and <i>RhoA-ROCK</i> signalling. <i>Nature Communications</i> , 2018, 9, 254.	12.8	55
17	Telomere sequence content can be used to determine ALT activity in tumours. <i>Nucleic Acids Research</i> , 2018, 46, 4903-4918.	14.5	40
18	Guidelines for whole genome bisulphite sequencing of intact and FFPE DNA on the Illumina HiSeq X Ten. <i>Epigenetics and Chromatin</i> , 2018, 11, 24.	3.9	38

#	ARTICLE	IF	CITATIONS
19	Regulation of the interferon-gamma (IFN- γ) pathway by p63 and β 133p53 isoform in different breast cancer subtypes. <i>Oncotarget</i> , 2018, 9, 29146-29161.	1.8	16
20	Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 1-14.	5.1	20
21	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
22	Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences. <i>Cell Death and Disease</i> , 2017, 8, e2755-e2755.	6.3	41
23	BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres. <i>EMBO Journal</i> , 2017, 36, 2907-2919.	7.8	127
24	MatCol: a tool to measure fluorescence signal colocalisation in biological systems. <i>Scientific Reports</i> , 2017, 7, 8879.	3.3	14
25	Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. <i>Cell Reports</i> , 2017, 19, 2544-2556.	6.4	75
26	Comparative analysis of whole genome sequencing-based telomere length measurement techniques. <i>Methods</i> , 2017, 114, 4-15.	3.8	43
27	The C-Circle Assay for alternative-lengthening-of-telomeres activity. <i>Methods</i> , 2017, 114, 74-84.	3.8	95
28	Functional dissection of breast cancer risk-associated <i>TERT</i> promoter variants. <i>Oncotarget</i> , 2017, 8, 67203-67217.	1.8	21
29	Abstract A22: Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency. , 2017, , .		0
30	Is cell culture a risky business? Risk analysis based on scientist survey data. <i>International Journal of Cancer</i> , 2016, 138, 664-670.	5.1	7
31	A Study of <i>TP53</i> RNA Splicing Illustrates Pitfalls of RNA-seq Methodology. <i>Cancer Research</i> , 2016, 76, 7151-7159.	0.9	29
32	DNA methylation mediated up-regulation of <i>TERRA</i> non-coding RNA is coincident with elongated telomeres in the human placenta. <i>Molecular Human Reproduction</i> , 2016, 22, 791-799.	2.8	28
33	A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase. <i>PLoS Genetics</i> , 2015, 11, e1005286.	3.5	35
34	Stanniocalcin-1 Inhibits Renal Ischemia/Reperfusion Injury via an AMP-Activated Protein Kinase-Dependent Pathway. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 364-378.	6.1	65
35	Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. <i>Clinical Epigenetics</i> , 2015, 7, 52.	4.1	26
36	Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 875-880.	8.2	174

#	ARTICLE	IF	CITATIONS
37	STC1 expression is associated with tumor growth and metastasis in breast cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 15-27.	3.3	95
38	ATRX represses alternative lengthening of telomeres. <i>Oncotarget</i> , 2015, 6, 16543-16558.	1.8	135
39	Senescence and Immortalization. , 2015, , 4174-4177.		0
40	Telomere Maintenance Mechanisms in Cancer: Clinical Implications. <i>Current Pharmaceutical Design</i> , 2014, 20, 6361-6374.	1.9	74
41	NuRDâ€™ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 760-770.	8.2	101
42	Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. <i>Nucleic Acids Research</i> , 2014, 42, 1733-1746.	14.5	92
43	Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein. <i>Experimental Cell Research</i> , 2014, 322, 324-334.	2.6	25
44	Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3062-71.	7.1	31
45	Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1. <i>Blood</i> , 2014, 124, 2767-2774.	1.4	97
46	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
47	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 1287-1297.	0.9	144
48	Alternative lengthening of telomeres: remodeling the telomere architecture. <i>Frontiers in Oncology</i> , 2013, 3, 27.	2.8	78
49	Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. <i>Neuroscience</i> , 2013, 229, 49-54.	2.3	28
50	Alternative lengthening of telomeres in normal mammalian somatic cells. <i>Genes and Development</i> , 2013, 27, 18-23.	5.9	111
51	Detection of alternative lengthening of telomeres by telomere quantitative PCR. <i>Nucleic Acids Research</i> , 2013, 41, e34-e34.	14.5	75
52	Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway. <i>PLoS Genetics</i> , 2012, 8, e1002772.	3.5	489
53	Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. <i>Journal of Cell Biology</i> , 2012, 199, 893-906.	5.2	129
54	Five dysfunctional telomeres predict onset of senescence in human cells. <i>EMBO Reports</i> , 2012, 13, 52-59.	4.5	178

#	ARTICLE	IF	CITATIONS
55	Enhanced isolation of fibroblasts from human skin explants. <i>BioTechniques</i> , 2012, 53, 239-244.	1.8	26
56	The role of telomere trimming in normal telomere length dynamics. <i>Cell Cycle</i> , 2012, 11, 1309-1315.	2.6	53
57	Cancer and Telomeres—An Alternative to Telomerase. <i>Science</i> , 2012, 336, 1388-1390.	12.6	127
58	Extreme Telomere Length Dimorphism in the Tasmanian Devil and Related Marsupials Suggests Parental Control of Telomere Length. <i>PLoS ONE</i> , 2012, 7, e46195.	2.5	27
59	Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres. <i>PLoS ONE</i> , 2012, 7, e50062.	2.5	64
60	Telomerase activity in pleural malignant mesotheliomas. <i>Lung Cancer</i> , 2011, 73, 283-288.	2.0	20
61	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e24987.	2.5	48
62	Normal mammalian cells negatively regulate telomere length by telomere trimming. <i>Human Molecular Genetics</i> , 2011, 20, 4684-4692.	2.9	87
63	MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. <i>Nucleic Acids Research</i> , 2011, 39, 8078-8091.	14.5	42
64	HP1-Mediated Formation of Alternative Lengthening of Telomeres-Associated PML Bodies Requires HIRA but Not ASF1a. <i>PLoS ONE</i> , 2011, 6, e17036.	2.5	25
65	Senescence and Immortalization. , 2011, , 3371-3373.		0
66	Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 729-736.	1.7	76
67	Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. <i>FEBS Letters</i> , 2010, 584, 3800-3811.	2.8	206
68	Check your cultures! A list of cross-contaminated or misidentified cell lines. <i>International Journal of Cancer</i> , 2010, 127, 1-8.	5.1	404
69	Alternative lengthening of telomeres: models, mechanisms and implications. <i>Nature Reviews Genetics</i> , 2010, 11, 319-330.	16.3	815
70	Senescence: an antiviral defense that is tumor suppressive?. <i>Carcinogenesis</i> , 2010, 31, 19-26.	2.8	52
71	Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. <i>Human Molecular Genetics</i> , 2009, 18, 1017-1027.	2.9	59
72	Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. <i>Journal of Cell Biology</i> , 2009, 185, 797-810.	5.2	43

#	ARTICLE	IF	CITATIONS
73	DNA Replication Licensing and Progenitor Numbers Are Increased by Progesterone in Normal Human Breast. <i>Endocrinology</i> , 2009, 150, 3318-3326.	2.8	122
74	Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. <i>Nucleic Acids Research</i> , 2009, 37, 1152-1159.	14.5	137
75	Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1. <i>Journal of Cell Science</i> , 2009, 122, 2989-2995.	2.0	9
76	Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. <i>Human Molecular Genetics</i> , 2009, 18, 3098-3109.	2.9	65
77	Control of telomere length by a trimming mechanism that involves generation of t-circles. <i>EMBO Journal</i> , 2009, 28, 799-809.	7.8	178
78	DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. <i>Nature Biotechnology</i> , 2009, 27, 1181-1185.	17.5	406
79	Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1244-1251.	8.2	220
80	Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. <i>Oncogene</i> , 2009, 28, 2678-2689.	5.9	13
81	Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. <i>Oncogene</i> , 2009, 28, 1982-1992.	5.9	52
82	Alternative Lengthening of Telomeres in Human Cells. , 2009, , 127-148.		1
83	Telomere uncapping and alternative lengthening of telomeres. <i>Mechanisms of Ageing and Development</i> , 2008, 129, 99-108.	4.6	108
84	A sensitive direct human telomerase activity assay. <i>Nature Methods</i> , 2008, 5, 355-360.	19.0	58
85	Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. <i>Cancer Science</i> , 2008, 99, 1092-1099.	3.9	147
86	PAX8 Regulates Telomerase Reverse Transcriptase and Telomerase RNA Component in Glioma. <i>Cancer Research</i> , 2008, 68, 5724-5732.	0.9	39
87	Amplification of Telomerase Reverse Transcriptase Gene in Human Mammary Epithelial Cells with Limiting Telomerase RNA Expression Levels. <i>Cancer Research</i> , 2008, 68, 3115-3123.	0.9	18
88	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 4134-4140.	7.0	61
89	The Murine Stanniocalcin 2 Gene Is a Negative Regulator of Postnatal Growth. <i>Endocrinology</i> , 2008, 149, 2403-2410.	2.8	82
90	Chimerism and Tolerance in a Recipient of a Deceased-Donor Liver Transplant. <i>New England Journal of Medicine</i> , 2008, 358, 2075-2075.	27.0	1

#	ARTICLE	IF	CITATIONS
91	Disruption of Telomere Maintenance by Depletion of the MRE11/RAD50/NBS1 Complex in Cells That Use Alternative Lengthening of Telomeres. <i>Journal of Biological Chemistry</i> , 2007, 282, 29314-29322.	3.4	133
92	DNA Damage Induces Alternative Lengthening of Telomeres (ALT)â€“Associated Promyelocytic Leukemia Bodies that Preferentially Associate with Linear Telomeric DNA. <i>Cancer Research</i> , 2007, 67, 7072-7077.	0.9	78
93	Concordant Epigenetic Silencing of Transforming Growth Factor- β^2 Signaling Pathway Genes Occurs Early in Breast Carcinogenesis. <i>Cancer Research</i> , 2007, 67, 11517-11527.	0.9	76
94	Protein Composition of Catalytically Active Human Telomerase from Immortal Cells. <i>Science</i> , 2007, 315, 1850-1853.	12.6	595
95	Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. <i>Oncogene</i> , 2007, 26, 4635-4647.	5.9	102
96	A SUMO ligase for ALT. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 570-571.	8.2	4
97	Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. <i>International Journal of Cancer</i> , 2006, 118, 2973-2980.	5.1	214
98	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. <i>Cancer Research</i> , 2006, 66, 8918-8924.	0.9	115
99	Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma. <i>Cancer Research</i> , 2006, 66, 6473-6476.	0.9	72
100	The Murine Stanniocalcin 1 Gene Is Not Essential for Growth and Development. <i>Molecular and Cellular Biology</i> , 2005, 25, 10604-10610.	2.3	58
101	Telomerase-Independent Telomere Length Maintenance in the Absence of Alternative Lengthening of Telomeresâ€“Associated Promyelocytic Leukemia Bodies. <i>Cancer Research</i> , 2005, 65, 2722-2729.	0.9	90
102	Suppression of Alternative Lengthening of Telomeres by Sp100-Mediated Sequestration of the MRE11/RAD50/NBS1 Complex. <i>Molecular and Cellular Biology</i> , 2005, 25, 2708-2721.	2.3	141
103	Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. <i>Human Molecular Genetics</i> , 2005, 14, 1785-1794.	2.9	27
104	hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. <i>Nucleic Acids Research</i> , 2005, 33, 486-496.	14.5	74
105	The first molecular details of ALT in human tumor cells. <i>Human Molecular Genetics</i> , 2005, 14, R191-R196.	2.9	186
106	A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. <i>Clinical Cancer Research</i> , 2005, 11, 217-25.	7.0	191
107	Alternative Lengthening of Telomeres Is Characterized by High Rates of Telomeric Exchange. <i>Cancer Research</i> , 2004, 64, 2324-2327.	0.9	283
108	Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. <i>Oncogene</i> , 2004, 23, 3116-3121.	5.9	51

#	ARTICLE	IF	CITATIONS
109	Telomere Biology: A New Player in the End Zone. <i>Current Biology</i> , 2004, 14, R901-R902.	3.9	27
110	Molecular Markers and Long-term Survivors of Glioblastoma Multiforme. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	2.0	1
111	Human POT1 Facilitates Telomere Elongation by Telomerase. <i>Current Biology</i> , 2003, 13, 942-946.	3.9	195
112	Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. <i>Lancet, The</i> , 2003, 361, 836-838.	13.7	245
113	Alternative lengthening of telomeres: dangerous road less travelled. <i>Lancet, The</i> , 2003, 361, 1840-1841.	13.7	39
114	Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. <i>Experimental Cell Research</i> , 2003, 286, 96-101.	2.6	93
115	Alternative lengthening of telomeres, telomerase, and cancer. <i>Cancer Letters</i> , 2003, 194, 155-162.	7.2	172
116	Mammalian stanniocalcins and cancer.. <i>Endocrine-Related Cancer</i> , 2003, 10, 359-373.	3.1	140
117	Telomeres and Cellular Aging. , 2003, , 171-205.		0
118	A Major Functional Difference between the Mouse and Human ARF Tumor Suppressor Proteins. <i>Journal of Biological Chemistry</i> , 2002, 277, 36665-36670.	3.4	29
119	CARF Is a Novel Protein That Cooperates with Mouse p19 (Human p14) in Activating p53. <i>Journal of Biological Chemistry</i> , 2002, 277, 37765-37770.	3.4	58
120	Hsp70 Family Member, mot-2/mthsp70/GRP75, Binds to the Cytoplasmic Sequestration Domain of the p53 Protein. <i>Experimental Cell Research</i> , 2002, 274, 246-253.	2.6	162
121	Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. <i>Oncogene</i> , 2002, 21, 128-139.	5.9	112
122	Alternative lengthening of telomeres in mammalian cells. <i>Oncogene</i> , 2002, 21, 598-610.	5.9	581
123	Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. <i>Nature Genetics</i> , 2002, 30, 301-305.	21.4	117
124	Telomere maintenance and cancer ? look, no telomerase. <i>Nature Reviews Cancer</i> , 2002, 2, 879-884.	28.4	135
125	Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. <i>Cancer Research</i> , 2002, 62, 1289-95.	0.9	107
126	Effects of Simian Virus 40 T-Antigens on Normal Human Mammary Epithelial Cells Reveal Evidence for Spontaneous Alterations in Addition to Loss of p16INK4a Expression. <i>Experimental Cell Research</i> , 2001, 265, 125-134.	2.6	11

#	ARTICLE	IF	CITATIONS
127	An N-terminal Region of Mot-2 Binds to p53 In Vitro. <i>Neoplasia</i> , 2001, 3, 110-114.	5.3	62
128	Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas. <i>Oncogene</i> , 2001, 20, 2600-2605.	5.9	16
129	Alternative Lengthening of Telomeres in Human Cells. <i>Radiation Research</i> , 2001, 155, 194-200.	1.5	104
130	Pex19p Dampens the p19ARF-p53-p21WAF1 Tumor Suppressor Pathway*. <i>Journal of Biological Chemistry</i> , 2001, 276, 18649-18652.	3.4	41
131	Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 3862-3875.	2.3	224
132	An alternative lifestyle for immortalized oral keratinocytes. <i>Journal of Clinical Investigation</i> , 2001, 108, 665-667.	8.2	9
133	Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. <i>Biochemical Journal</i> , 2000, 350, 453.	3.7	24
134	Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. <i>Biochemical Journal</i> , 2000, 350, 453-461.	3.7	72
135	Telomere maintenance by recombination in human cells. <i>Nature Genetics</i> , 2000, 26, 447-450.	21.4	792
136	The role of senescence and immortalization in carcinogenesis. <i>Carcinogenesis</i> , 2000, 21, 477-484.	2.8	205
137	Structurally and Functionally Distinct Mouse Hsp70 Family Members Mot-1 and Mot-2 Proteins are Encoded by Two Alleles. <i>DNA Research</i> , 2000, 7, 229-231.	3.4	25
138	Identification of a Novel Human Mitochondrial D-Loop RNA Species Which Exhibits Upregulated Expression Following Cellular Immortalization. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 439-446.	2.1	9
139	Transcriptional Inactivation of p53 by Deletions and Single Amino Acid Changes in Mouse mot-1 Protein. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 602-606.	2.1	16
140	p53 Localizes to the Centrosomes and Spindles of Mitotic Cells in the Embryonic Chick Epiblast, Human Cell Lines, and a Human Primary Culture: An Immunofluorescence Study. <i>Experimental Cell Research</i> , 2000, 256, 122-130.	2.6	79
141	Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. <i>FEBS Letters</i> , 2000, 474, 159-164.	2.8	73
142	The hTERT [±] Splice Variant is a Dominant Negative Inhibitor of Telomerase Activity. <i>Neoplasia</i> , 2000, 2, 426-432.	5.3	194
143	p16INK4a and the control of cellular proliferative life span. <i>Carcinogenesis</i> , 1999, 20, 921-926.	2.8	100
144	Cloning and Characterization of a Novel Gene, striamin, That Interacts with the Tumor Suppressor Protein p53. <i>Journal of Biological Chemistry</i> , 1999, 274, 14948-14955.	3.4	5

#	ARTICLE	IF	CITATIONS
145	Constructing immortalized human cell lines. <i>Current Opinion in Biotechnology</i> , 1999, 10, 465-469.	6.6	40
146	Downregulation of metallothionein-IIA expression occurs at immortalization. <i>Oncogene</i> , 1999, 18, 897-903.	5.9	23
147	Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. <i>Oncogene</i> , 1999, 18, 3383-3390.	5.9	100
148	Inhibition of SV40 large T antigen induced apoptosis by small T antigen. <i>Oncogene</i> , 1999, 18, 5598-5603.	5.9	32
149	Expression and localisation of stanniocalcin 1 in rat bladder, kidney and ovary. <i>Electrophoresis</i> , 1999, 20, 2071-2076.	2.4	18
150	A reassessment of the telomere hypothesis of senescence. <i>BioEssays</i> , 1999, 20, 977-984.	2.5	57
151	Telomere maintenance mechanisms and cellular immortalization. <i>Current Opinion in Genetics and Development</i> , 1999, 9, 97-103.	3.3	165
152	Identification of a 55-kDa Ezrin-Related Protein That Induces Cytoskeletal Changes and Localizes to the Nucleolus. <i>Experimental Cell Research</i> , 1999, 250, 51-61.	2.6	27
153	Malignant transformation of NIH3T3 cells by overexpression of mot-2 protei. <i>Oncogene</i> , 1998, 17, 907-911.	5.9	86
154	Genes Involved in the Control of Cellular Proliferative Potentiala. <i>Annals of the New York Academy of Sciences</i> , 1998, 854, 8-19.	3.8	44
155	Differential display of mRNA. <i>Molecular Biotechnology</i> , 1998, 10, 155-165.	2.4	48
156	Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. <i>Molecular and Cellular Endocrinology</i> , 1998, 141, 95-99.	3.2	102
157	Telomere Length Dynamics in Telomerase-Positive Immortal Human Cell Populations. <i>Experimental Cell Research</i> , 1998, 239, 370-378.	2.6	107
158	Human Stanniocalcin (STC): Genomic Structure, Chromosomal Localization, and the Presence of CAG Trinucleotide Repeats. <i>Genomics</i> , 1998, 47, 393-398.	2.9	31
159	Correction of the Copper Transport Defect of Menkes Patient Fibroblasts by Expression of the Menkes and Wilson ATPases. <i>Journal of Biological Chemistry</i> , 1998, 273, 31375-31380.	3.4	97
160	Inactivation of Tumor Suppressor p53 by Mot-2, a hsp70 Family Member. <i>Journal of Biological Chemistry</i> , 1998, 273, 29586-29591.	3.4	207
161	Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types. <i>Human Molecular Genetics</i> , 1997, 6, 2011-2019.	2.9	524
162	The Telomere Lengthening Mechanism in Telomerase-Negative Immortal Human Cells Does Not Involve the Telomerase RNA Subunit. <i>Human Molecular Genetics</i> , 1997, 6, 921-926.	2.9	179

#	ARTICLE	IF	CITATIONS
163	Telomere dynamics and telomerase activity in in vitro immortalised human cells. <i>European Journal of Cancer</i> , 1997, 33, 767-773.	2.8	203
164	Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. <i>Nature Medicine</i> , 1997, 3, 1271-1274.	30.7	1,157
165	Reassessment of immortalization complementation group D. <i>Experimental Gerontology</i> , 1997, 32, 663-670.	2.8	5
166	Normal telomere maintenance in immortal ataxia telangiectasia cell lines. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1997, 379, 177-184.	1.0	27
167	Telomeres in the Haemopoietic System. <i>Novartis Foundation Symposium</i> , 1997, 211, 209-226.	1.1	14
168	Genetic Differences between the Pancytosolic and Perinuclear Forms of Murine Mortalin. <i>Experimental Cell Research</i> , 1996, 226, 381-386.	2.6	26
169	Characteristics of tumor cell bioactivity in oncogenic osteomalacia. <i>Molecular and Cellular Endocrinology</i> , 1996, 124, 17-23.	3.2	57
170	Molecular cloning and characterization of mouse stanniocalcin cDNA. <i>Molecular and Cellular Endocrinology</i> , 1996, 124, 185-187.	3.2	80
171	An effective elimination of false positives isolated from differential display of mRNAs. <i>Molecular Biotechnology</i> , 1996, 6, 213-217.	2.4	8
172	Chromosomal changes and progressive tumorigenesis of human bronchial epithelial cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1996, 92, 99-110.	1.0	15
173	Sv40-induced immortalization and transformation of human bronchial epithelial cells. <i>International Journal of Cancer</i> , 1995, 61, 199-205.	5.1	45
174	Immortalization techniques. <i>Cytotechnology</i> , 1995, 17, 65-66.	0.7	1
175	Immortalization of human fibroblasts by liposome-mediated transfer of SV40 early region genes. <i>Cytotechnology</i> , 1995, 17, 75-81.	0.7	8
176	Genetic changes during immortalization of human cells. <i>Radiation Oncology Investigations</i> , 1995, 3, 299-306.	0.9	0
177	A novel human cDNA highly homologous to the fish hormone stanniocalcin. <i>Molecular and Cellular Endocrinology</i> , 1995, 112, 241-247.	3.2	200
178	Correlation between Complementation Group for Immortality and the Cellular Distribution of Mortalin. <i>Experimental Cell Research</i> , 1995, 216, 101-106.	2.6	81
179	HPV-16 E6 and E7 Genes, like SV40 Early Region Genes, Are Insufficient for Immortalization of Human Mesothelial and Bronchial Epithelial Cells. <i>Experimental Cell Research</i> , 1994, 213, 418-427.	2.6	28
180	Assignment of SV40-Immortalized Cells to More Than One Complementation Group for Immortalization. <i>Experimental Cell Research</i> , 1993, 205, 337-344.	2.6	56

#	ARTICLE	IF	CITATIONS
181	Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. <i>Carcinogenesis</i> , 1992, 13, 1359-1363.	2.8	8
182	Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. <i>Experimental Cell Research</i> , 1992, 203, 297-304.	2.6	29
183	A human bronchial epithelial cell strain with unusual in vitro growth potential which undergoes neoplastic transformation after SV40 T antigen gene transfection. <i>International Journal of Cancer</i> , 1991, 48, 764-773.	5.1	11
184	Oncogenes and Tumor Suppressor Genes Involved in Human Lung Carcinogenesis. , 1990, 53, 363-379.		5
185	Enhancement of the invasive ability of a transformed human bronchial epithelial cell line by 12-O-tetra-decanoyl-phorbol-13-acetate and diacylglycerol. <i>Carcinogenesis</i> , 1989, 10, 2335-2338.	2.8	19
186	Invasive and Metastatic Potential of a v-Ha-ras-Transformed Human Bronchial Epithelial Cell Line. <i>Journal of the National Cancer Institute</i> , 1989, 81, 587-594.	6.3	94
187	Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. <i>Differentiation</i> , 1988, 38, 60-66.	1.9	164
188	Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral harvey <i>ras</i>. <i>Molecular Carcinogenesis</i> , 1988, 1, 151-160.	2.7	68
189	Cell cycle effects of iron depletion on T-47D human breast cancer cells. <i>Experimental Cell Research</i> , 1985, 161, 277-284.	2.6	28
190	Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 1419-1424.	0.7	103
191	N-Desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in Vitro. <i>European Journal of Cancer & Clinical Oncology</i> , 1983, 19, 1179-1181.	0.7	8
192	Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. <i>European Journal of Cancer & Clinical Oncology</i> , 1983, 19, 307-318.	0.7	90
193	Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. <i>European Journal of Cancer & Clinical Oncology</i> , 1983, 19, 615-621.	0.7	181
194	Alternative lengthening of telomeres in mammalian cells. , 0, .		4
195	Senescence and immortalization. , 0, , 2697-2699.		0
196	Stanniocalcin2, but Not Stanniocalcin1, Responds to Hypoxia in a HIF1-Dependent Manner in the Retina. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	3